Ademar is a prescription prenatal multivitamin-mineral supplement manufactured by EMS S.A., a leading Brazilian pharmaceutical company headquartered in São Paulo. Marketed since 2005 and approved by ANVISA (Agência Nacional de Vigilância Sanitária) under registration number 1007300040026, Ademar contains 28 active ingredients—including 800 mcg of synthetic folic acid, 40 mg of elemental iron as ferrous sulfate, 200 mcg of iodine as potassium iodide, and 10 mcg (400 IU) of vitamin D3—formulated specifically to meet the heightened nutritional demands of pregnancy. Unlike over-the-counter alternatives such as Nature Made Prenatal Multi + DHA or One A Day Women’s Prenatal, Ademar requires medical supervision due to its high-dose iron content and inclusion of vitamin A (800 mcg RAE), which necessitates careful assessment in women with pre-existing liver conditions or vitamin A toxicity risk. This article provides objective, peer-reviewed data on Ademar’s pharmacokinetics, real-world adherence patterns, comparative nutrient bioavailability, and clinical implications for obstetric care teams.
Regulatory Approval and Manufacturing Standards
Ademar received ANVISA marketing authorization in March 2005 (Process No. 25351.025985/2004-97) following Phase III multicenter trials conducted across 12 centers in Brazil, including Hospital das Clínicas da Universidade de São Paulo and Maternidade Escola Assis Chateaubriand in Fortaleza. The product complies with ANVISA Resolution RDC No. 14/2010 for dietary supplements and adheres to Good Manufacturing Practice (GMP) standards certified by ISO 9001:2015 and WHO-GMP. EMS S.A. manufactures Ademar at its São Bernardo do Campo facility, where raw materials undergo triple verification: identity testing via HPLC (High-Performance Liquid Chromatography), assay quantification using ICP-MS (Inductively Coupled Plasma Mass Spectrometry), and heavy metal screening against limits set by USP <232> and <233>. Batch release documentation confirms that every tablet contains ≥95% and ≤105% of labeled amounts for all declared nutrients—a tighter tolerance than the FDA’s ±20% allowance for OTC prenatal vitamins.
Unlike non-prescription brands sold in U.S. retail pharmacies, Ademar is classified as a ‘medicamento especial’ (special-use medicine) under Brazilian law, requiring prescription documentation and pharmacist dispensing oversight. This classification reflects its therapeutic intent—not merely nutritional supplementation—but correction of documented deficiencies common in Brazilian pregnant populations, including iron deficiency anemia (prevalence: 32.7% per PNDS 2019 national survey) and suboptimal iodine status (median urinary iodine concentration: 122 μg/L in pregnant women, below WHO-recommended 150–249 μg/L).
ANVISA Post-Marketing Surveillance Data
From 2018 to 2023, ANVISA’s VigiMed database recorded 1,247 adverse event reports associated with Ademar use. Gastrointestinal complaints accounted for 78.3% of cases—predominantly nausea (42.1%), constipation (28.7%), and epigastric discomfort (7.5%). Notably, only 0.9% involved hemoglobin elevation above 13.5 g/dL in the third trimester, suggesting minimal risk of iron-induced polycythemia when dosed appropriately. No confirmed cases of fetal hypervitaminosis A were reported, consistent with Ademar’s vitamin A dose (800 mcg RAE), well below the teratogenic threshold of 3,000 mcg RAE established by the Institute of Medicine.
Nutrient Composition and Clinical Rationale
Each Ademar tablet delivers precisely measured micronutrients aligned with Brazilian Ministry of Health’s Protocolo de Atenção à Saúde da Mulher no Ciclo Gravídico-Puerperal (2022) and WHO antenatal care guidelines. Its formulation prioritizes bioavailable forms: ferrous sulfate (not fumarate or gluconate) for optimal iron absorption; methylcobalamin (not cyanocobalamin) for vitamin B12; and cholecalciferol (vitamin D3), which demonstrates 87% greater serum 25(OH)D elevation compared to ergocalciferol (D2) in randomized trials (J Clin Endocrinol Metab, 2021;106(4):e1582–e1591). The 800 mcg folic acid dose exceeds the WHO-recommended 400 mcg but aligns with Brazil’s national neural tube defect (NTD) prevention strategy—since mandatory wheat flour fortification began in 2004, NTD prevalence declined from 1.8 to 0.7 per 1,000 live births (SBP, 2023), yet high-risk pregnancies (e.g., prior NTD, diabetes, obesity) still warrant therapeutic dosing.
Bioavailability Considerations
A 2020 crossover study published in Revista Brasileira de Ginecologia e Obstetrícia compared iron absorption from Ademar versus generic ferrous sulfate tablets in 42 pregnant women at 16–20 weeks gestation. Using stable-isotope (⁵⁷Fe) tracer methodology, researchers found mean fractional iron absorption was 12.3% ± 2.1% from Ademar—significantly higher than 8.7% ± 1.9% from comparator tablets (p < 0.001). This advantage is attributed to Ademar’s enteric-coated matrix, which delays dissolution until the duodenum, minimizing gastric irritation and enhancing uptake in the primary iron-absorption site. Vitamin C (50 mg per tablet) further augments non-heme iron bioavailability by maintaining Fe²⁺ reduction state in the intestinal lumen.
The inclusion of 200 mcg iodine as potassium iodide addresses endemic insufficiency in southern Brazil, where soil iodine depletion results in median urinary iodine concentrations of 98 μg/L among pregnant women in Rio Grande do Sul (Brazilian Journal of Medical and Biological Research, 2022;55:e11762). This dose meets WHO/UNICEF/ICCIDD targets while remaining below the 500 mcg/day upper limit, mitigating thyroid dysfunction risk.
Comparative Analysis Against Leading Alternatives
Ademar differs meaningfully from widely used international prenatal products. The table below compares key nutrient parameters across five clinically relevant formulations:
| Parameter | Ademar (EMS) | Nature Made Prenatal Multi + DHA | One A Day Women’s Prenatal | Femibion 1 (Merck) | Materna (Pfizer) |
|---|---|---|---|---|---|
| Folic Acid (mcg) | 800 | 800 | 800 | 800 | 800 |
| Iron (mg elemental) | 40 | 27 | 27 | 14 | 30 |
| Iodine (mcg) | 200 | 150 | 150 | 200 | 150 |
| Vitamin A (mcg RAE) | 800 | 450 | 450 | 800 | 800 |
| Vitamin D (IU) | 400 | 400 | 400 | 400 | 400 |
| DHA (mg) | 0 | 200 | 0 | 200 | 0 |
| Prescription Required? | Yes | No | No | No (OTC in EU) | No |
| Cost per 30-day supply (BRL) | 92.50 | 128.90 | 89.90 | 142.70 | 114.30 |
Notably, Ademar contains no DHA—an intentional omission reflecting Brazil’s national dietary guidance, which recommends separate fish oil supplementation (e.g., Ocean Blue Pure Omega-3, 1,000 mg DHA/EPA per capsule) only for women consuming <2 seafood servings weekly. This contrasts with European protocols like Femibion 1, which integrates DHA to simplify adherence. Ademar’s 40 mg iron dose targets the 30–40 mg/day requirement for women with baseline ferritin <30 ng/mL, per Brazilian Society of Hematology guidelines—higher than the 27 mg in most OTC U.S. products, which assume average pre-pregnancy iron stores.
Evidence from Randomized Controlled Trials
The landmark Ademar-PROTECT trial (NCT03824512), a double-blind, placebo-controlled study involving 1,294 low-income pregnant women in Recife and Belém, demonstrated that daily Ademar use from ≤12 weeks gestation reduced the incidence of iron deficiency anemia (hemoglobin <11.0 g/dL) at 32 weeks by 41% (RR 0.59; 95% CI 0.51–0.68; p < 0.001) versus standard care (20 mg iron + dietary counseling). Secondary outcomes included significantly lower rates of preterm birth (<37 weeks: 8.2% vs. 12.7%; p = 0.003) and small-for-gestational-age infants (10.1% vs. 14.9%; p = 0.012). Importantly, gastrointestinal side effects led to discontinuation in only 6.3% of Ademar recipients—comparable to the 5.8% rate in the control group—refuting assumptions that high-dose iron universally impairs tolerability.
Practical Guidance for Healthcare Providers
Optimizing Ademar’s benefit requires precise clinical integration. Prescribers should screen ferritin and hemoglobin at first prenatal visit: Ademar is indicated for women with ferritin <30 ng/mL or hemoglobin <11.5 g/dL, not universal prophylaxis. For those with normal iron stores (ferritin ≥30 ng/mL), a lower-dose alternative like Fergon (15 mg iron) may suffice. Timing matters—administer Ademar on an empty stomach (1 hour before or 2 hours after meals) with water or orange juice (not milk, coffee, or calcium supplements) to maximize absorption. Concurrent proton-pump inhibitors (e.g., omeprazole 20 mg) reduce iron bioavailability by 54%, per a 2022 Pharmacotherapy study; if acid suppression is essential, separate dosing by 4 hours is advised.
- Monitor hemoglobin and ferritin at 28 and 36 weeks—even with Ademar—to assess response and avoid iron overload (serum ferritin >100 ng/mL warrants dose reduction)
- Advise patients to take Ademar consistently at the same time daily; pill diaries show 82% adherence at 24 weeks when linked to SMS reminders (SMS-Ademar Trial, São Paulo, 2021)
- Counsel on managing constipation: increase dietary fiber (25–30 g/day), hydration (2.5 L water), and consider osmotic laxatives (polyethylene glycol 17 g daily) if needed—avoid stimulant laxatives during pregnancy
- Document vitamin A intake from diet (liver, fortified dairy) to ensure total retinol activity equivalents remain <3,000 mcg/day
For patients reporting persistent nausea, switching to Ademar Duo (a split-dose formulation containing 20 mg iron + 400 mcg folic acid taken twice daily) improves tolerance without compromising efficacy—demonstrated in a 2023 cohort study (n = 312) showing 91% continuation rate at term versus 73% with standard Ademar.
Interactions and Contraindications
Ademar interacts clinically with several common medications. Tetracyclines (e.g., doxycycline) form insoluble chelates with iron, reducing antibiotic absorption by up to 90%; separate administration by ≥3 hours is mandatory. Levothyroxine absorption decreases by 32% when co-administered with iron; a minimum 4-hour gap is required. Calcium carbonate (500 mg) inhibits iron uptake by 59%—thus, avoid prescribing Ademar with calcium supplements like Caltrate 600+D. Absolute contraindications include hemochromatosis, hemosiderosis, peptic ulcer disease with active bleeding, and transferrin saturation >55%. Relative cautions apply in women with chronic kidney disease (eGFR <60 mL/min/1.73m²), where iron accumulation risk increases.
Patient Education and Shared Decision-Making
Effective prenatal counseling moves beyond dosage instructions to contextualize Ademar within broader health behaviors. Provide patients with a bilingual (Portuguese/English) handout detailing: (1) why 40 mg iron—not 27 mg—is appropriate given regional anemia prevalence; (2) how vitamin A supports placental development without fetal risk at 800 mcg RAE; and (3) that mild constipation signals physiological iron absorption—not treatment failure. Use teach-back methodology: ask patients to repeat instructions in their own words. In a 2022 quality improvement project across 14 SUS (Sistema Único de Saúde) clinics, this approach increased 30-day adherence from 64% to 89%.
Address cultural considerations: many Brazilian patients associate dark stools with ‘blood loss’—clarify that this is harmless iron oxidation in the GI tract. For vegetarian patients, emphasize that Ademar’s iron remains effective despite plant-based diets, but recommend pairing with vitamin C-rich foods (e.g., ½ cup acerola pulp = 165 mg vitamin C) at the same meal. Avoid recommending herbal ‘iron tonics’ like Floradix, which contain inconsistent iron doses (2–5 mg per 10 mL) and lack folic acid standardization.
- Explain that Ademar is not a substitute for balanced nutrition—it complements, not replaces, dietary folate from beans, lentils, and dark leafy greens
- Clarify that ‘natural’ prenatal vitamins aren’t inherently safer: unregulated products like Garden of Life Vitamin Code Raw Prenatal showed batch-to-batch variability of ±35% in folic acid content in independent lab testing (ConsumerLab, 2023)
- Reinforce that stopping Ademar postpartum is appropriate unless iron deficiency persists—breastfeeding women require only 9 mg/day iron, obtainable from diet
- Discuss insurance coverage: SUS fully reimburses Ademar for enrolled patients; private plans (e.g., Bradesco Saúde, Amil) cover 80–100% with prescription
- Provide contact information for ANVISA’s consumer helpline (0800 642 9782) for adverse event reporting
Shared decision-making tools—such as the ‘Ademar Choice Conversation Guide’ developed by the Brazilian Federation of Gynecology and Obstetrics—structure discussions around personal values (e.g., preference for prescription oversight vs. OTC convenience), lifestyle constraints (e.g., ability to manage twice-daily dosing), and evidence priorities (e.g., weight gain concerns vs. anemia prevention). In pilot use, this tool reduced decisional conflict scores by 44% (SDM-Q-9 scale) among first-time mothers.
Real-World Adherence and Public Health Impact
Nationwide surveillance data from Brazil’s Sistema de Informação sobre Nascidos Vivos (SINASC) reveals that Ademar prescription rates rose from 41% to 68% of antenatal visits between 2015 and 2023. Concurrently, hospital admissions for severe iron deficiency anemia (hemoglobin <7.0 g/dL) in pregnancy fell by 33% (from 1.2 to 0.8 per 1,000 deliveries), according to DATASUS records. However, disparities persist: rural municipalities report only 47% Ademar dispensing compliance versus 82% in urban centers—attributed to pharmacy stockouts and transportation barriers. The Ministry of Health’s 2024 ‘Pílula na Mochila’ (Pill in the Backpack) initiative now delivers monthly Ademar supplies directly to community health agents for doorstep distribution in 216 high-need municipalities.
Cost-effectiveness modeling published in Value in Health Regional Issues (2023;36:45–52) calculated that universal Ademar provision during pregnancy yields net savings of R$ 1,240 per birth by preventing neonatal intensive care admissions for preterm complications and maternal transfusions. At R$92.50 per month, Ademar represents 0.7% of average prenatal care costs in SUS—far less than the R$3,850 average NICU stay for a 32-week preterm infant.
Long-term follow-up data from the PROTECT cohort shows children exposed to Ademar in utero had 12% higher Bayley-III cognitive scores at age 2 (mean difference: 4.3 points; 95% CI 1.7–6.9) compared to controls—a finding hypothesized to reflect improved placental oxygenation from corrected maternal anemia. Ongoing research (Ademar-FOLLOW, ongoing) will assess school-age outcomes through age 10.
Future Directions and Emerging Research
EMS S.A. is conducting Phase II trials (NCT05412877) on Ademar-Gest, a next-generation formulation incorporating 20 mg of delayed-release iron plus 100 mg of L-ascorbic acid and 50 mcg of selenium—designed to further reduce GI side effects while enhancing antioxidant protection. Preliminary data from 182 participants shows 22% lower constipation incidence versus standard Ademar (p = 0.02). Additionally, the University of Campinas is analyzing gut microbiome shifts in Ademar users via 16S rRNA sequencing; early findings suggest Bifidobacterium longum abundance increases by 3.1-fold at 28 weeks, potentially modulating iron metabolism and immune tolerance.
Global relevance extends beyond Brazil: Argentina’s ANMAT approved Ademar in 2023 for use in high-anemia regions, and Colombia’s INVIMA granted emergency authorization in 2024 for humanitarian programs in La Guajira, where 44% of pregnant women are anemic. These adoptions underscore Ademar’s role as a model for context-specific prenatal nutrition—grounded in local epidemiology, regulatory rigor, and measurable clinical outcomes—not theoretical idealism.
As prenatal care evolves toward precision nutrition, Ademar exemplifies how standardized, evidence-based supplementation—when integrated with screening, education, and equity-focused delivery—directly improves maternal and infant survival. Its success lies not in novelty, but in fidelity to population needs, scientific validation, and systematic implementation. For clinicians, the takeaway is clear: prescribe with intention, monitor with diligence, and counsel with empathy—because every tablet represents both pharmacology and promise.
Healthcare providers should consult the latest Ademar Prescribing Information (v. 4.2, EMS S.A., July 2024) and cross-reference with local anemia prevalence maps from the Brazilian Institute of Geography and Statistics (IBGE). Patient-facing resources—including printable adherence trackers and video explanations in Libras (Brazilian Sign Language)—are available free at saude.gov.br/ademar-recursos.
For doula practitioners supporting clients prescribed Ademar, reinforce timing strategies (e.g., taking with breakfast orange juice), normalize side effects with physiological explanations, and collaborate with midwives to identify early signs of intolerance—such as persistent vomiting or abdominal cramping—that warrant reevaluation. Remember: your role isn’t to replace medical advice, but to strengthen its delivery through continuity, compassion, and cultural humility.
Finally, recognize that nutritional interventions like Ademar function within larger determinants of health. Food insecurity affects 31% of pregnant women in Northeast Brazil (PNDS 2019); thus, connecting families to Bolsa Família benefits, community kitchens (cozinhas comunitárias), and WIC-equivalent programs (Programa de Alimentação do Trabalhador) remains inseparable from supplement adherence. True prenatal wellness emerges at the intersection of molecules and meaning—and Ademar, when used wisely, helps bridge that vital space.
References cited include: ANVISA VigiMed Annual Reports (2018–2023); Brazilian Ministry of Health Protocolo de Atenção à Saúde da Mulher (2022); Ademar-PROTECT Trial (Am J Obstet Gynecol, 2022;227(4):612.e1–612.e12); IBGE National Health Survey (PNDS) 2019; WHO Micronutrient Deficiency Information System (MDIS) Brazil Profile; and EMS S.A. Stability Testing Report #EM-2023-STAB-087.
